Summary & Overview
HCPCS J0602: Sevelamer Carbonate Oral Powder 20 mg for ESRD on Dialysis
HCPCS Level II code J0602 designates sevelamer carbonate (Renvela or therapeutically equivalent), oral powder, 20 mg, used to manage hyperphosphatemia in patients with end-stage renal disease on dialysis. This code identifies a pharmacy-dispensed oral phosphate binder commonly used in dialysis programs and outpatient pharmacy settings. Nationally, accurate coding for J0602 matters for medication access, payer coverage determinations, and standardized reporting of ESRD outpatient pharmaceutical therapy.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for sevelamer carbonate in dialysis-dependent patients, common coverage considerations across major payers, and what to expect in billing practice for outpatient pharmacy dispensing. The publication also outlines benchmarks and policy-relevant updates where available, and highlights typical sites of service and service line classification for administrative workflows.
The content provides concise guidance on the clinical and billing identity of J0602, clarifies its role in ESRD management, and summarizes payer coverage landscape at a national level. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0602 represents sevelamer carbonate (Renvela or therapeutically equivalent), oral, powder, 20 mg intended for patients with end-stage renal disease (ESRD) on dialysis. The service type is oral phosphate binder medication administered as an outpatient pharmacy-dispensed product for chronic management of hyperphosphatemia in dialysis-dependent patients. The typical site of service is outpatient pharmacy or dialysis clinic outpatient dispensing, where the medication is provided for oral administration by the patient during or between dialysis sessions.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with end-stage renal disease on maintenance hemodialysis who has hyperphosphatemia. The patient receives a prescription for sevelamer carbonate oral powder (J0602) to be taken with meals to control serum phosphate and reduce the risk of vascular calcification. The clinical workflow begins in the nephrology clinic or dialysis unit: serum phosphate level is measured during routine labs, the nephrologist documents persistent hyperphosphatemia despite diet and other measures, and prescribes sevelamer carbonate powder with dose and administration instructions. Pharmacy dispenses the oral powder formulation, and nursing or dialysis staff provide patient education on mixing and timing with meals. Follow-up includes monitoring serum phosphate, calcium, parathyroid hormone, and assessing tolerance and adherence at subsequent dialysis visits or nephrology follow-up. Billing for the drug uses J0602 for sevelamer carbonate oral powder per 20 mg unit, with appropriate site-of-service codes reflecting outpatient dialysis clinics, hospital outpatient dialysis units, or community pharmacies for take-home prescriptions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Original service | When no modifier applies and the service is billed as reported. |